|Bid||4,100.50 x 51000|
|Ask||4,230.00 x 53800|
|Day's range||4,182.00 - 4,230.00|
|52-week range||2,940.50 - 4,894.00|
|PE ratio (TTM)||8.63|
|Forward dividend & yield||0.25 (0.62%)|
|1y target est||N/A|
For Christophe Weber, the boss of Japan's Takeda Pharmaceutical , securing a $62 billion (46 billion pound) deal last week to buy drugmaker Shire (SHP.L) at the fifth time of asking was the easy bit. At the same time he must win shareholders' support for the largest-ever overseas purchase by a Japanese company - something he told Reuters could be helped by bringing in one or more long-term, large strategic investor.
For Christophe Weber, the boss of Japan's Takeda Pharmaceutical, securing a $62 billion deal last week to buy drugmaker Shire (Xetra: S7E.DE - news) at the fifth time of asking was the easy bit. At the same time he must win shareholders' support for the largest-ever overseas purchase by a Japanese company - something he told Reuters could be helped by bringing in one or more long-term, large strategic investor. When you combine two pipelines you can be more stringent," he said in London, where he is meeting investors and analysts.
In May, Jazz Pharmaceuticals (JAZZ) submitted a supplemental new drug application (or sNDA) to the FDA for the label expansion of Xyrem for the inclusion of its use in the treatment of cataplexy and EDS (excessive daytime sleepiness) in pediatric patients with narcolepsy. In April, Jazz Pharmaceuticals entered into an agreement with Spark Therapeutics (ONCE) whereby Jazz would purchase a rare pediatric disease priority review voucher for $110 million that would allow it to accelerate the FDA review process for one of its future regulatory submissions. Of the 23 analysts tracking Jazz Pharmaceuticals in May, six have recommended “strong buys” on the stock, while 13 have recommended “buys.” Four analysts have recommended “holds” on Jazz Pharmaceuticals in May.
In 1Q18, Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million compared to $376.1 million in 1Q17, which reflected an ~18% rise on a YoY (year-over-year) basis and a ~2% rise quarter-over-quarter.
Takeda Pharmaceutical Co.’s ambitions for expansion in the lucrative U.S. health-care market led the Japanese drugmaker to begin a painstaking examination of Shire Plc’s assets more than two years prior to striking a $62 billion deal. In particular, Shire’s neuroscience unit and its gastrointestinal products sparked Takeda’s interest. Shire’s struggling stock performance after its failed sale to AbbVie Inc. and the acquisition spree that followed, culminating with the $32 billion takeover of Baxalta Inc., frustrated investors and prompted concerns about its strategy.
Takeda Pharmaceutical Co. investors may belatedly be coming around to the view that the $62 billion purchase of Shire Plc is the best thing that could have happened to the Japanese drugmaker. To get the same U.S. exposure, and generate cost savings, Takeda might have looked to Celgene Corp. or Biogen Inc., according to Datamonitor Healthcare analyst Edward Thomason. Tack on the 65 percent premium Takeda offered Shire shareholders and you’re talking an awful lot of money.
Takeda Pharmaceutical Co.’s credit rating was downgraded by Moody’s Investors Service one day after the Japanese drugmaker said it had reached a deal to buy larger rival Shire Plc for about $62 billion. Takeda’s debt rating was cut to A2 from A1 on Wednesday, bringing it down one notch to the sixth-highest investment-grade level. Chief Executive Officer Christophe Weber capped a drawn-out pursuit of the U.K.-listed company on Tuesday, announcing an acquisition that will give Takeda wider reach into the U.S., the world’s biggest drug market, and strengthen its global pipeline.
Takeda Pharmaceutical Co.’s Chief Executive Officer Christophe Weber navigated rebuffs, critics and a plunging stock price to win a $62 billion deal to acquire larger rival Shire Plc. Integrating the Japanese drugmaker -- which began by selling herbal therapies 237 years ago -- with the sprawling American company will be even more complicated. As the Osaka-based company’s first foreign head, Weber is overseeing a dramatic makeover that will reshape Takeda into a global powerhouse with a plum suite of drugs for rare diseases.
Takeda Pharmaceutical Co. on Tuesday reached an agreement to buy Shire PLC, capping a monthslong battle for control of the European drugmaker and marking the biggest-ever overseas acquisition by a Japanese company. Shire’s board agreed Takeda could buy it at £49.01 or $66.21 a share—$30.33 in cash and 0.839 of a Takeda share for each Shire share—in a deal that valued the target at $62 billion. The acquisition would create the world’s eighth-largest drugmaker with combined sales worth $30 billion, and bolsters Takeda Chief Executive Christophe Weber’s mission to gain a greater foothold in more lucrative markets such as the U.S. and Europe.
Crude prices pared losses that earlier on Tuesday ran as deep as 4 percent after U.S. President Donald Trump said the United States will withdraw from the Iran nuclear deal, while the dollar edged off fresh 2018 highs. Brent futures, the global crude benchmark, briefly turned positive after Trump announced the U.S. withdrawal from the 2015 international agreement aimed at stopping Iran from obtaining a nuclear bomb.
U.K. stocks booked a tiny loss Tuesday, as oil-and-gas shares fell along with oil futures ahead of a closely watched decision on a resumption of Iranian sanctions by the U.S. However, the day’s loss was limited by optimism over a $62 billion takeover offer for Shire.
Shares of European oil companies finished lower Tuesday as traders waited for U.S. President Donald Trump’s final decision on the Iran nuclear deal, but a gauge of the broader equity market pulled out ...
Takeda Pharmaceutical Co Ltd. agreed Tuesday to purchase rare-disease drugmaker Shire Plc for $62 billion. But this blockbuster deal comes with blockbuster risk. Takeda will be paying a steep premium and taking on big debt to acquire a company with uncertain prospects. Shire’s hemophilia business provides more than a quarter of its revenue.
Dealmaking dominated activity in UK stocks, with gains in Shire and Virgin Money, although the FTSE 100 index held steady after a public holiday and ended flat at 7,565.75 points. A weaker pound had encouraged ...
Drugs firm Shire (Xetra: S7E.DE - news) has agreed on the terms of a £46bn takeover by Japan's Takeda in one of the sector's biggest ever deals. Shire had said last month that it was "willing to recommend" the proposal - the fifth offer in a series of improved bids - subject to certain conditions being met. The deal is expected to result in $1.4bn annual cost savings and will prompt a "review of the functions to be undertaken" at Shire's headquarters in Dublin as well as possible "consolidation" of operations in the US, Singapore and Switzerland.
The U.S. dollar hit fresh 2018 highs on Tuesday on safe-haven demand amid expectations President Donald Trump will pull out of a key nuclear accord with Iran, while oil prices slumped ahead of news on whether the U.S. will reinstate sanctions on Iran. U.S. officials indicated late Monday that Trump would withdraw from the deal but it was unclear on what terms and whether sanctions would be announced, said a senior European official closely involved in Iran diplomacy. Equity markets in the U.S. and Europe edged lower, weighed by technology and consumer discretionary stocks, as investors awaited Trump's decision at 2:00 p.m. ET (1800 GMT).
Some pharma stocks are on the rise today, following earnings and Shire's (SHPG) $62 billion takeover deal, but the goodwill didn't spread to all regions of the sector. Valeant Pharmaceuticals International (VRX) delivered a beat-and-raise first quarter, saying it earned 89 cents a share on revenue of $2 billion, while analysts expected EPS of 60 cents on revenue of $1.95 billion. For the full year, it now sees revenue of $8.15 billion to $8.35 billion, up from its previous $8.1 billion-$8.3 billion range, and above the $8.23 billion consensus estimate.
A $62 billion health-care mega deal has catapulted Evercore Inc., the boutique advisory firm founded by former Lehman Brothers banker Roger Altman, into the No. 5 slot on the global M&A league tables.
Takeda clinched the $62 billion acquisition of Ireland-based drugmaker Shire after a six-week back-and-forth.
LONDON/TOKYO (Reuters) - Takeda Pharmaceutical agreed to buy London-listed Shire for 45.3 billion pounds ($62 billion) on Tuesday, the biggest yet in a wave of deals sweeping the drugs industry. Assuming it wins the backing of shareholders, the deal will be the largest overseas purchase by a Japanese company and propel Takeda, led by Frenchman Christophe Weber, into the top 10 rankings of global drugmakers. Shire has profitable businesses selling drugs for hyperactivity and rare disorders but the size of the deal will make Takeda one of the most indebted drugmakers, prompting Standard & Poor's to warn of a potential credit downgrade.